• Welcome
  • The Board
  • Our Investors
  • soloMER Technology
  • Licensing Opportunities
  • Pipeline
  • Publications
  • Contact
  • News
ELASMOGEN
Elasmogen announces a panel of novel, potent, anti-Covid-19 therapeutic candidates identified through collaboration with U.S. research partners

Elasmogen announces a panel of novel, potent, anti-Covid-19 therapeutic candidates identified through collaboration with U.S. research partners

by elasmogen | Jan 25, 2021 | News

At only one tenth the size of traditional antibodies new VNAR biologics could be used to both treat and protect against SARSCoV-2 infections January 25th 2021: Aberdeen, Scotland:  Elasmogen Ltd, the pioneering biopharmaceutical company leading the development of VNAR...

News archives

  • May 2025
  • March 2025
  • December 2024
  • June 2024
  • April 2024
  • November 2023
  • June 2023
  • May 2023
  • April 2023
  • December 2022
  • September 2022
  • May 2022
  • December 2021
  • September 2021
  • January 2021
  • December 2020
  • July 2020
  • May 2020
  • April 2020
  • February 2020
  • January 2020
  • December 2019
  • November 2019
  • July 2019
  • May 2019
  • March 2019
  • January 2019
  • December 2018
  • November 2018
  • October 2018
  • August 2018
  • May 2018
  • January 2018
  • November 2017
  • May 2017
  • March 2017
  • January 2017
  • August 2016
  • July 2016
  • March 2016
  • December 2015
  • Follow
welcome
the board
our investors
soloMER® technology
licensing opportunities
pipeline
publications
contact
news

Liberty Building
Foresterhill Health Campus
Foresterhill Rd
Aberdeen AB25 2ZP

t: (+44) 070 7721 0755